• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 11, 2015

View Archived Issues

See if Ikaria: Mallinckrodt drug-device stand not partial post-$1.3B Therakos ECP buyout

Although the buyout of Therakos Inc. for about $1.3 billion is the second drug-device acquisition by Mallinckrodt plc this year, it's because of the synergies between the two firms involved in the deals rather than a preference for such technology per se. Read More

Editas lands $120M to advance CRISPR/Cas9 platform in oversubscribed series B

Genome-editing start-up Editas Medicine Inc. has raised $120 million in an oversubscribed series B financing to advance its discovery-stage programs and platform in one of the year's biggest private financings. Read More

Astrazeneca in I-O three-peat with $727.5M Inovio deal

Last week, Astrazeneca plc tapped Mirati Therapeutics Inc. for a partnership that will explore a pairing of the spectrum-selective histone deacetylase, or HDAC, blocker mocetinostat with the anti-programmed death-ligand 1 (PD-L1) candidate durvalumab (MEDI4736). Read More

Judge tells FDA to loosen speech bans: You got Caronia wrong

A federal district judge shot down the FDA's attempts to marginalize the Second Circuit's Caronia ruling in justifying its continued censorship of drugmakers' truthful comments about off-label uses of their products. Read More

'Clean sheet' Ocata advancing RPE cells in SMD, AMD trials

LONDON – Ocata Therapeutics Inc. is poised to start phase II trials of its human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in the treatment of macular degeneration, which the company said will be the first such ophthalmic studies to feature placebo-controlled arms. Read More

Novavax showcases RSV vaccine success in elder-targeted phase II

A phase II trial of an experimental respiratory syncytial virus (RSV) vaccine created by Novavax Inc. prevented symptoms of the common and sometimes deadly virus in as many as 46 percent of older adults, giving the company a strong foundation ahead of a planned pivotal phase III trial that could start as early as the fourth quarter and boding well for another program testing the vaccine to protect infants via maternal immunization scheduled to report data in September. Read More

Chemical reprogramming can transform skin cells into neurons

HONG KONG – Two stem cell labs in China have independently reported the successful transformation of fibroblasts into functional neurons using only chemicals, with one group using human cells from healthy individuals and Alzheimer's patients, while the other used mouse cells, potentially providing other sources of neuronal cells for drug discovery and regenerative medicine. Read More

Karyopharm sinks on AML sepsis rates, says other trials not affected

Shares of Karyopharm Therapeutics Inc. hit a new 52-week low Monday on news that a higher-than-expected rate of sepsis prompted the Newton, Mass.-based firm to reduce the dose in an ongoing phase IIb study testing selinexor in elderly patients with acute myeloid leukemia (AML). Read More

Financings

Zynerba Pharmaceuticals Inc., of Devon, Pa., said it closed its IPO of 3.45 million shares priced at $14 each, including the exercise in full by underwriters to purchase up to 450,000 additional shares, resulting in gross proceeds of $48.3 million. Read More

Other news to note

Anavex Life Sciences Corp., of New York, said it received a research grant from the Michael J. Fox Foundation for Parkinson's Research for Anavex 2-73, which is being studied for Parkinson's disease. Read More

Stock movers

Read More

In the clinic

Gamida Cell Ltd., of Jerusalem, reached agreements with the FDA and European regulators regarding the phase III study design outline of Nicord. Read More

Popular Stories

  • Telomeres and DNA illustration

    23andme founder-led group outbids Regeneron for company

    BioWorld
    The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
  • Today's news in brief

    BioWorld
    BioWorld briefs for June 17, 2025.
  • Sarepta signage

    Elevidys’ second liver death hits Sarepta, sends DMD ripples

    BioWorld
    How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 17, 2025.
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe